Mr. Martino Ciambrelli reports

VANTA CLOSES SECOND TRANCHE OF PRIVATE PLACEMENT FINANCING AND WELCOMES LAUNCH OF FIRST U.S.-LISTED PEPTIDE ETF, HIGHLIGHTING GROWING RECOGNITION OF PEPTIDE INDUSTRY

Further to the news releases dated May 29, 2026, and Aug. 21, 2026, Vanta Holdings Inc. has closed, effective Oct. 15, 2026, the second tranche of its previously announced non-brokered private placement through the issuance of 210,000 units of the company at a price of $1 per unit for aggregate gross proceeds of $210,000. Each unit consists of one common share in the capital of the company and one transferable common share purchase warrant. Each warrant entitles the holder to acquire one additional share at an exercise price of $1.25 per warrant share, exercisable until Oct. 15, 2028.

The securities issued under the private placement will be subject to a statutory hold period expiring Feb. 17, 2027. In connection with the closing of the second tranche, the company paid aggregate cash finders' fees of $1,500 to registered dealers.

The net proceeds of the private placement are intended to be allocated toward the payment of outstanding and future payables and indebtedness, including amounts owing to related parties, and corporate awareness.

Together with the closing of the first tranche of the private placement, the company has raised aggregate gross proceeds of $334,579.42 through the issuance of an aggregate of 334,579 units pursuant to the private placement. The second tranche constitutes the final tranche of the private placement.

Launch of first United States-listed peptide exchange-traded fund

The company welcomes the Oct. 14, 2026, launch of the Nasdaq-listed REX Peptide ETF by REX Shares. Described by its sponsor as the first U.S.-listed pure play peptide exchange-traded fund, the ETF provides diversified exposure to companies engaged in the development, manufacturing, delivery and commercialization of peptide-based products. It tracks the VettaFi Peptide Index, which comprised 36 constituents as of Sept. 30, 2026.

Vanta believes the introduction of a dedicated peptide ETF reflects growing recognition of peptide-based innovation across a broad range of therapeutic, health care and consumer wellness applications. The company is not affiliated with REX Shares or the REX Peptide ETF, and the ETF's launch does not imply any investment in, endorsement of or commercial relationship with Vanta.

Vanta's position in the evolving peptide industry

Vanta has established a strategic operating framework and infrastructure relationships to support its planned U.S.-focused peptide platform. As disclosed in its news release dated May 28, 2026, the company, through its indirect wholly owned subsidiary, Vanta Amino Sciences Inc., entered into a master service, commercialization and strategic operations agreement with an arm's-length strategic operating partner.

The agreement establishes a framework for co-ordinating compounding pharmacy relationships, peptide manufacturing and fulfilment capabilities, compliant payment processing infrastructure, and telehealth-enabled commercialization support. Commercialization remains subject to adequate financing, compliance with applicable regulatory requirements and the execution of definitive commercial agreements, as applicable.

The planned platform complements Vanta's existing nutraceutical and premium functional hydration portfolio and forms part of its broader consumer health sciences and longevity strategy.

About Vanta Holdings Inc.

Vanta Holdings is a consumer health sciences and longevity company advancing an integrated ecosystem of U.S.-focused peptide therapy, nutraceutical and premium hydration products centred on preventative wellness and healthspan extension, positioning the company to participate in the rapidly expanding longevity economy.

Vanta is advancing a U.S.-focused telehealth-enabled peptide therapy and longevity platform leveraging commercialization infrastructure and Food and Drug Administration-registered 503A and 503B compounding pharmacy relationships to pursue initiatives across recovery, metabolic wellness, performance optimization and healthy aging categories.

Through its Vanta brand and select private-label partnerships, the company develops, manufactures and distributes premium hydration and longevity-oriented nutraceutical products, including, without limitation, its flagship proprietary Blackwater and BlackPowder product portfolio featuring bioactive compounds, trace mineral complexes and patented fulvic isolation technology designed to support hydration, mineral replenishment, cellular function, immune function, gut health, nutrient absorption, cognitive function and broader everyday wellness-focused applications aligned with growing consumer demand for functional health optimization products. Vanta's vertically integrated operations include ownership of a natural alkaline spring water aquifer and a 40,000-square-foot Health Canada- and HACCP-certified manufacturing facility situated in the mountains of British Columbia.

We seek Safe Harbor.